Participating Companies

Institut de la Màcula
The Institut de la Màcula is an international benchmark in the treatment of medical and surgical pathologies of the macula, retina and vitreous and forms part of the Hospital Quirón Teknon. The use of state of the art techniques and treatments in different specialties places the centre at the forefront of treating and handling sight disorders. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
US$394 MM MCap
Cell therapy company with 3 clnical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

University of California, Los Angeles (UCLA)
The University of California, Los Angeles, is a public research university located in Los Angeles, California, United States. [more information]